Amyotrophic Lateral Sclerosis

Shionogi Announces $2.5 Billion Acquisition of ALS Drug Radicava from Tanabe Pharma

6 days ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, Infrequent, Radicava, shionogi, Tanabe Pharma

Shionogi; Tanabe Pharma; Radicava; ALS; acquisition; $2.5B; rare disease

NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

1 month ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, AstroRx ®, Barrow Neurological Institute, Cell Therapy, Clinical Trials, Jeremy Shefner, Neurodegenerative Disorders, NewcelX, Scientific Advisory Board

NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

2 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

4 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biotechnology, epigenetic therapy, Epigenic, Gene Silencing, Hepatitis B, Hypercholesterolemia, Investments, NRG, Parkinson Disease, Series B funding

Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

4 months ago talkbio0Tagged AMX0035, Amylyx, Amyotrophic Lateral Sclerosis, Clinical trial failure, Discontinuation (procedure), disease program, Infrequent, Placebos, Progressive, Relyvrio, Supranuclear paralysis

Amylyx; Relyvrio; AMX0035; progressive supranuclear palsy; ALS; clinical trial failure; rare disease program; placebo; discontinuation

FDA Delays Draw Contrasting Responses: Neurizon Cites Agency Strain, Omeros Takes Softer Tone

4 months ago talkbio0Tagged agency staffing shortages, Amyotrophic Lateral Sclerosis, delays, narsoplimab, NUZ-001, Omeros Corporation, regulatory review, Study on Hold, Transplantation, United States Food and Drug Administration

FDA delays; Neurizon Therapeutics; Omeros Corporation; regulatory review; NUZ-001; narsoplimab; ALS; transplant drugs; agency staffing shortages; clinical hold